Drug Profile


Alternative Names: IVAC MUTANOME; Melanoma RNA vaccine personalised - BioNTech/Ribological/TRON; Personalised melanoma vaccine - BioNTech/TRON

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioNTech; Ribological; TRON
  • Class Cancer vaccines; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Malignant melanoma

Most Recent Events

  • 06 Sep 2017 BioNTech, TRON and EUFETS plan a phase I trial for Breast cancer (Second-line therapy or greater) in Germany, Belgium, Sweden and France
  • 05 Jul 2017 Efficacy data from a phase I trial in Malignant melanoma released by BioNTech
  • 01 Sep 2016 Phase-I clinical trials in Breast cancer in Germany (Intralymphatic) (NCT02316457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top